| Accession |
PRJCA021879 |
| Title |
EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA MUTANT |
| Relevance |
Medical |
| Data types |
Variation
|
| Organisms |
Homo sapiens
|
| Description |
a phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with pik3ca mutant, hormone receptor positive, her2 negative locally advanced or metastatic breast cancer |
| Sample scope |
Multiisolate |
| Release date |
2023-12-19 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Roche/Genetech
|
|
N/A
|
|
|
|
| Submitter |
Jiong
Wu (wujiong1122@vip.sina.com)
|
| Organization |
Fudan University Shanghai Cancer Center |
| Submission date |
2023-12-08 |
